Abstract
Antimicrobial peptides are an important class of therapeutic agents used against a wide range of pathogens such as gram-negative and -positive bacteria, fungi, and viruses. The minimal inhibitory concentration at the level of the pathogen membrane is a major determinant of the pharmacokinetic behavior and, consequently, it can affect their antimicrobial activity. Here we generated quantitative structure-activity relationship models (3D-QSAR—comparative molecular field analysis/comparative molecular similarity indices analysis) using a database of 33 mastoparan analogs, antimicrobial peptides with known experimental activity, and further used these models to predict the minimal inhibitory concentration for 18 new mastoparan analogs, obtained by computational mutagenesis. We discuss two options for structural alignment of mastoparan analogs: superposition of Cα trace atoms or superposition of all backbone atoms. Significant values of the cross-validated correlation q 2 (higher than 0.60) and the fitted correlation r 2 (higher than 0.90) of our models indicate that they are reliable enough for activity prediction in the case of new derivatives. This allows us to identify compounds with possibly enhanced antimicrobial activity against Bacillus subtilis, which are suggested for further experimental studies.
Graphical Abstract
Similar content being viewed by others
References
Hilpert K, Elliott MR, Volkmer-Engert R, Henklein P, Donini O, Zhou Q, Winkler DF, Hancock RE (2006) Chem Biol 13:1101
Rodriguez CH, De Ambrosio A, Bajuk M, Spinozzi M, Nastro M, Bombicino K, Radice M, Gutkind G, Vay C, Famiglietti A (2010) J Infect Dev Countries 4:164
Bals R, Hubert D, Tummler B (2011) J Cystic Fibrosis 10(Suppl 2):S146
Opatowski L, Guillemot D, Boelle PY, Temime L (2011) Curr Opin Infect Dis 24:279
Zhu WL, Song YM, Park Y, Park KH, Yang ST, Kim JI, Park IS, Hahm KS, Shin SY (2007) Biochim Biophys Acta 1768:1506
Zasloff M (2002) Nature 415:389
Zanetti M, Gennaro R, Skerlavaj B, Tomasinsig L, Circo R (2002) Curr Pharm Design 8:779
Kolar SS, McDermott AM (2011) Cell Mol Life Sci 68:2201
Bernard JJ, Gallo RL (2011) Cell Mol Life Sci 68:2189
Maher S, McClean S (2006) Biochem Pharmacol 71:1289
Rosenfeld Y, Lev N, Shai Y (2010) Biochemistry 49:853
Harris F, Dennison SR, Phoenix DA (2009) Curr Protein Pept Sci 10:585
Hancock RE, Rozek A (2002) FEMS Microbiol Lett 206:143
Jin Y, Hammer J, Pate M, Zhang Y, Zhu F, Zmuda E, Blazyk J (2005) Antimicrob Agents Chemother 49:4957
Mahalka AK, Kinnunen PK (2009) Biochim Biophys Acta 1788:1600
Leptihn S, Har JY, Wohland T, Ding JL (2010) Biochemistry 49:9161
Yin F, Kindt JT (2010) J Phys Chem B 114:8076
Cruciani RA, Barker JL, Zasloff M, Chen HC, Colamonici O (1991) Proc Natl Acad Sci USA 88:3792
Mally M, Majhenc J, Svetina S, Zeks B (2007) Biochim Biophys Acta 1768:1179
Dempsey CE, Hawrani A, Howe RA, Walsh TR (2010) Protein Pept Lett 17:1334
Nan YH, Bang JK, Shin SY (2009) Peptides 30:832
Cerovsky V, Slaninova J, Fucik V, Hulacova H, Borovickova L, Jezek R, Bednarova L (2008) Peptides 29:992
Cerovsky V, Pohl J, Yang Z, Alam N, Attygalle AB (2007) J Pept Sci 13:445
dos Santos Cabrera MP, Costa ST, de Souza BM, Palma MS, Ruggiero JR, Ruggiero Neto J (2008) Eur Biophys J 37:879
Cabrera MP, Alvares DS, Leite NB, de Souza BM, Palma MS, Riske KA, Neto JR (2011) Amino Acids 40:77
Leite NB, da Costa LC, dos Santos Alvares D, dos Santos Cabrera MP, de Souza BM, Palma MS, Neto JR (2011) Amino Acids 40:91
Mikut R (2010) Methods Mol Biol 618:287
Tong J, Liu S, Zhou P, Wu B, Li Z (2008) J Theor Biol 253:90
Jenssen H, Fjell CD, Cherkasov A, Hancock RE (2008) J Pept Sci 14:110
Collantes ER, Dunn WJ (1995) J Med Chem 38:2705
Avram S, Duda-Seiman D, Borcan F, Radu B, Duda-Seiman C, Mihailescu D (2011) Int J Pept Res Ther 17:7
Persson B (2000) EXS 88:215
Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA (1995) J Am Chem Soc 117:5179
Akamatsu M (2002) Curr Top Med Chem 2:1381
Checler F, Alves da Costa C, Ayral E, Andrau D, Dumanchin C, Farzan M, Hernandez JF, Martinez J, Lefranc-Jullien S, Marambaud P, Pasini A, Petit A, Phiel C, Robert P, St. George-Hyslop P, Wilk S (2005) Curr Alzheimer Res 2:327
Sybyl 7 (2010) http://www.tripos.com; accessed 21 Oct 2011
Hayashi Y, Sakaguchi K, Kobayashi M, Kikuchi Y, Ichiishi E (2003) Bioinformatics 19:1514
Oprea TI, Waller CL, Marshall GR (1994) J Med Chem 37:2206
Cramer RD, Patterson DE, Bunce JD (1989) Prog Clin Biol Res 291:161
Klebe G, Abraham U, Mietzner T (1994) J Med Chem 37:4130
Khedkar SA, Malde AK, Coutinho EC (2007) J Mol Model 13:1099
Acknowledgments
We acknowledge the financial support of CNMP PNII 61-016/2007, CNMP PNII 62-061/2008, and PNII PD-586/2010. A.-L. Milac was supported by the Romanian Academy project 3 of the Institute of Biochemistry of the Romanian Academy. A.-L. Milac acknowledges the postdoctoral program POSDRU/89/1.5/S/60746 from the European Social Fund.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Avram, S., Mihailescu, D., Borcan, F. et al. Prediction of improved antimicrobial mastoparan derivatives by 3D-QSAR-CoMSIA/CoMFA and computational mutagenesis. Monatsh Chem 143, 535–543 (2012). https://doi.org/10.1007/s00706-011-0713-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00706-011-0713-1